Humacyte, Inc. Common Stock HUMA
i
Market dataready · fetched 2026-11-11T15:34:39.973Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:34:22.503468025Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T15:34:39.191344+00:00
Humacyte, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 0.95 | 139.0% | 61.8% | 2.07 | 768.2% | 93.3% |
| 30Δ | 0.91 | 136.7% | 56.5% | 2.16 | 730.4% | 85.3% |
| 35Δ | 0.87 | 134.4% | 51.2% | 2.24 | 692.6% | 77.3% |
| 40Δ | 0.82 | 132.1% | 45.9% | 2.33 | 654.8% | 69.3% |
| 45Δ | 0.78 | 129.7% | 40.5% | 2.41 | 617.0% | 61.3% |
| 50Δ | 0.74 | 127.4% | 35.2% | 2.50 | 579.2% | 53.3% |
| 55Δ | 0.69 | 125.1% | 29.9% | 2.58 | 541.4% | 45.3% |
| 60Δ | 0.65 | 122.8% | 24.6% | 2.67 | 503.6% | 37.3% |
| 65Δ | 0.61 | 120.4% | 19.2% | 2.75 | 465.8% | 29.3% |
| 70Δ | 0.56 | 118.1% | 13.9% | 2.84 | 428.0% | 21.3% |
| 75Δ | 0.52 | 115.8% | 8.6% | 2.92 | 390.2% | 13.3% |
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 0.95
- IV
- 139.0%
- B/E move
- 61.8%
- Pseudo strike
- 2.07
- IV
- 768.2%
- B/E move
- 93.3%
30Δ
- Pseudo strike
- 0.91
- IV
- 136.7%
- B/E move
- 56.5%
- Pseudo strike
- 2.16
- IV
- 730.4%
- B/E move
- 85.3%
35Δ
- Pseudo strike
- 0.87
- IV
- 134.4%
- B/E move
- 51.2%
- Pseudo strike
- 2.24
- IV
- 692.6%
- B/E move
- 77.3%
40Δ
- Pseudo strike
- 0.82
- IV
- 132.1%
- B/E move
- 45.9%
- Pseudo strike
- 2.33
- IV
- 654.8%
- B/E move
- 69.3%
45Δ
- Pseudo strike
- 0.78
- IV
- 129.7%
- B/E move
- 40.5%
- Pseudo strike
- 2.41
- IV
- 617.0%
- B/E move
- 61.3%
50Δ
- Pseudo strike
- 0.74
- IV
- 127.4%
- B/E move
- 35.2%
- Pseudo strike
- 2.50
- IV
- 579.2%
- B/E move
- 53.3%
55Δ
- Pseudo strike
- 0.69
- IV
- 125.1%
- B/E move
- 29.9%
- Pseudo strike
- 2.58
- IV
- 541.4%
- B/E move
- 45.3%
60Δ
- Pseudo strike
- 0.65
- IV
- 122.8%
- B/E move
- 24.6%
- Pseudo strike
- 2.67
- IV
- 503.6%
- B/E move
- 37.3%
65Δ
- Pseudo strike
- 0.61
- IV
- 120.4%
- B/E move
- 19.2%
- Pseudo strike
- 2.75
- IV
- 465.8%
- B/E move
- 29.3%
70Δ
- Pseudo strike
- 0.56
- IV
- 118.1%
- B/E move
- 13.9%
- Pseudo strike
- 2.84
- IV
- 428.0%
- B/E move
- 21.3%
75Δ
- Pseudo strike
- 0.52
- IV
- 115.8%
- B/E move
- 8.6%
- Pseudo strike
- 2.92
- IV
- 390.2%
- B/E move
- 13.3%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
IBRX
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
More →IDYA
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected…
More →IFRX
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is…
More →IGC
India Globalization Capital, Inc. buys and resells physical infrastructure commodities. The company is headquartered in Potomac, Maryland.
More →IMCR
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is…
More →IMMX
Description unavailable
More →